SCHEMBL160824

SCHEMBL160824

CCOC(=O)CC1CCC(c2ncc(-c3ccc(NC(=O)c4ccc(Cl)cc4Cl)cc3)s2)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.41
RAB9A P51151 2/20 0.41
NPC1 O15118 1/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
POLB P06746 1/20 0.41
HSD11B1 P28845 2/20 0.40
CSF1R P07333 1/20 0.40
ACR P10323 1/20 0.40
MAPT P10636 1/20 0.40
TAS1R3 Q7RTX0 1/20 0.39
TAS1R1 Q7RTX1 1/20 0.39
CCR2 P41597 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
JAK2 O60674 1/20 0.39
JAK1 P23458 1/20 0.39
TYK2 P29597 1/20 0.39
AVPR2 P30518 1/20 0.39
GPR27 Q9NS67 1/20 0.39
HPGD P15428 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL162108 0.88 DGAT1 (0.45) MEN1KMT2APOLBCSF1RMAPT
SCHEMBL174454 0.87 CNR2 (0.38) MEN1KMT2APOLBMAPTJAK2
SCHEMBL161469 0.80 DGAT1 (0.49) RAB9ANPC1MEN1KMT2AMAPT
SCHEMBL163102 0.79 L3MBTL1 (0.42) RAB9ANPC1MEN1KMT2AMAPT
SCHEMBL161945 0.78 DGAT1 (0.51) RAB9ANPC1MEN1KMT2AMAPT
SCHEMBL162246 0.78 DGAT1 (0.41) RAB9ANPC1MEN1KMT2AMAPT
SCHEMBL174183 0.78 SMN1; SMN2 (0.41) RAB9ANPC1MEN1KMT2AMAPT
SCHEMBL161058 0.77 DGAT1 (0.40) MEN1KMT2APOLBCSF1RL3MBTL1
SCHEMBL161358 0.77 DGAT1 (0.52) RAB9ANPC1MAPT
SCHEMBL159620 0.77 KDM4E (0.49) RAB9AMEN1KMT2APOLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2611783-A2 HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS Piramal Enterprises Limited (IN) 2013-07-10 EP claimed
US-20130158075-A1 HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS Piramal Enterprises Limited (IN) 2013-06-20 US claimed
WO-2012029032-A2 HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS PIRAMAL LIFE SCIENCES LIMITED (IN) 2012-03-08 WO claimed
EP-2611783-A2 HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS Piramal Enterprises Limited (IN) 2013-07-10 EP disclosed
US-20130158075-A1 HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS Piramal Enterprises Limited (IN) 2013-06-20 US disclosed
WO-2012029032-A2 HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS PIRAMAL LIFE SCIENCES LIMITED (IN) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158075-A1 HETEROCYCLIC COMPOUNDS AS DGAT1 INHIBITORS DGAT1, DGAT2, SOAT1 TP53 1654/4885RAB9A 1781/4885NPC1 86/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.